Head of Clinical Development
Quotient Therapeutics
This listing was originally posted on Quotient Therapeutics's careers page. Formulate is an equal opportunity job aggregator and is not involved in the hiring process. Where salary information is estimated, it is derived from BLS industry benchmarks and may differ from actual compensation.
Upgrade to Pro to access the AI-generated 'Read before applying' briefing and other premium pharma intelligence.
Upgrade to Pro — $25/moWhat if… you could join an organization that creates, resources, and builds life sciences companies that invent breakthrough technologies in order to transform health care and sustainability?
Montai Therapeutics is a privately held, biotechnology company focused on harnessing AI to decode untapped diverse chemistry to develop breakthrough oral medicines that can address persistent unmet needs in chronic disease. With our CONECTA™ platform, Montai has built the world’s leading foundation models for decoding the complex language between nature’s bioactive chemistry and human biology – supercharging the drug discovery process with unprecedented optionality and predictability.
The company has curated and annotated a collection of over 1B Anthromolecules™ and Anthrologs™, which are derived from molecules humans have chronically consumed in food, supplements and herbal medicines. This has enabled efficient access to chemistry with vast untapped structural diversity and the potential to selectively and precisely modulate complex biology. Montai is rapidly advancing a pipeline of first-in-class oral medicines for validated biological pathways in inflammation and immunology – focused on biologic replacements and historically difficult to drug transcription factors.
Position Summary:
We are looking for an experienced Head of Clinical Development, reporting to our Chief Executive Officer, to have overall accountability for the development and implementation of small molecule clinical programs in the therapeutic areas of immunology/inflammation at Montai Therapeutics. We are seeking a highly motivated, collaborative, results-oriented individual with the creativity, resourcefulness, and flexibility to excel in our growing organization.
Specifically, the Head of Clinical Development will play a pivotal role in driving the successful transition of programs from research to clinical development and will contribute to shaping the clinical strategies that span from candidate discovery to human proof-of-concept. As a leader of our clinical development strategy, this role is responsible for crafting and integrating clinical development plans in alignment with research, translational, nonclinical, regulatory and strategic priorities. This individual will also ultimately oversee those responsible for supporting program operations, resource planning, and interactions with internal governance and external partners. This role is ideal for an experienced individual passionate about translating cutting-edge science into innovative medicines through rigorous, thoughtful and collaborative development planning and execution.
Key Responsibilities:
Required Experience:
Desired Skills & Competencies:
Location: Cambridge, MA
More About Flagship Pioneering
Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $50B in aggregate value. To date, Flagship has deployed over $2.2B in capital toward the founding and growth of its pioneering companies alongside more than $18B of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including Axcella Health (NASDAQ: AXLA), Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics (NASDAQ: FHTX), Indigo Ag, Kaleido Biosciences (NASDAQ: KLDO), Moderna (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology, Seres Therapeutics (NASDAQ: MCRB), and Sigilon Therapeutics (NASDAQ: SGTX).
The salary range for this role is $360,000 - $415,000. Compensation for the role will depend on a number of factors, including a candidate’s qualifications, skills, competencies, and experience. Montai Therapeutics currently offers healthcare coverage, annual incentive program, retirement benefits and a broad range of other benefits. Compensation and benefits information is based on Montai Therapeutics's good faith estimate as of the date of publication and may be modified in the future.
Explore related positions you might be interested in
We'll notify you when matching roles are posted.
Interviewed at Quotient Therapeutics?
Help others prepare — share your experience anonymously.
BIOTECHNOLOGY
Genetic Library
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo